pI: 9.3804 |
Length (AA): 123 |
MW (Da): 14000 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There is 1 model calculated for this protein. More info on
this model, including the
model itself is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
15 | 123 | 3m86 (A) | 0 | 123 | 98.00 | 0 | 1 | 2.08488 | -1.28 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Trophozoite, Rahman HM-1 IMSS Trophozoite. | Hon CC |
Hon CC | Transcriptomics of virulent and avirulent strains |
Ortholog group members (OG5_136685)
Species | Accession | Gene Product |
---|---|---|
Cryptosporidium hominis | Chro.60226 | transmembrane protein |
Cryptosporidium parvum | cgd6_1910 | conserved hypothetical protein |
Entamoeba histolytica | EHI_159600 | cysteine protease inhibitor 1 (EhICP1) |
Entamoeba histolytica | EHI_040460 | cysteine protease inhibitor 2 (EhICP2) |
Leishmania braziliensis | LbrM.24.1840 | inhibitor of cysteine peptidase |
Leishmania donovani | LdBPK_241840.1 | inhibitor of cysteine peptidase |
Leishmania infantum | LinJ.24.1840 | inhibitor of cysteine peptidase |
Leishmania major | LmjF.24.1770 | inhibitor of cysteine peptidase |
Leishmania mexicana | LmxM.24.1770 | inhibitor of cysteine peptidase |
Trypanosoma brucei gambiense | Tbg972.8.6530 | inhibitor of cysteine peptidase, putative,ICP, putative |
Trypanosoma brucei | Tb927.8.6450 | inhibitor of cysteine peptidase |
Trypanosoma cruzi | TcCLB.506801.80 | cysteine peptidase inhibitor |
Trypanosoma cruzi | TcCLB.511907.200 | cysteine peptidase inhibitor, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.8.6450 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.8.6450 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.8.6450 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.8.6450 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Leishmania major | inhibitor of cysteine peptidase | Compounds | References |